- Home
- LGVN vs ACCS Comparison
LGVN vs ACCS Comparison
Compare LGVN & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGVN | ACCS |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United States |
| Employees | N/A | 91 |
| Industry | Medicinal Chemicals and Botanical Products | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 28.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LGVN | ACCS |
|---|---|---|
| Price | $0.86 | $7.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 468.2K | 6.0K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,000.00 | N/A |
| Revenue This Year | N/A | $7.40 |
| Revenue Next Year | $10.81 | $8.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $6.51 |
| 52 Week High | $1.80 | $13.35 |
Technical Indicators
Market Signals| Indicator | LGVN | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 44.26 |
| Support Level | $0.74 | $6.77 |
| Resistance Level | $0.99 | $8.99 |
| Average True Range (ATR) | 0.05 | 0.47 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 9.20 | 48.57 |
Price Performance
Historical ComparisonAbout LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.